192 related articles for article (PubMed ID: 2529941)
21. Interaction of vasopressin and prostaglandins in the toad urinary bladder.
Bisordi JE; Schlondorff D; Hays RM
J Clin Invest; 1980 Dec; 66(6):1200-10. PubMed ID: 6777397
[TBL] [Abstract][Full Text] [Related]
22. Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase.
Chen WC; Chen CC
Endocrinology; 1999 Apr; 140(4):1639-48. PubMed ID: 10098498
[TBL] [Abstract][Full Text] [Related]
23. Arginine vasopressin-induced sensitization in brain: facilitated inositol phosphate production without changes in receptor number.
Poulin P; Pittman QJ
J Neuroendocrinol; 1993 Feb; 5(1):23-31. PubMed ID: 8485541
[TBL] [Abstract][Full Text] [Related]
24. Hepatic vasopressin receptor: differential effects of divalent cations, guanine nucleotides, and N-ethylmaleimide on agonist and antagonist interactions with the V1 subtype receptor.
Gopalakrishnan V; McNeill JR; Sulakhe PV; Triggle CR
Endocrinology; 1988 Aug; 123(2):922-31. PubMed ID: 2969327
[TBL] [Abstract][Full Text] [Related]
25. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes.
Torres BA; Johnson HM
J Immunol; 1988 Apr; 140(7):2179-83. PubMed ID: 2965181
[TBL] [Abstract][Full Text] [Related]
26. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.
Liard JF
Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987
[TBL] [Abstract][Full Text] [Related]
27. Human retinal pigment epithelial cells possess V1 vasopressin receptors.
Friedman Z; Delahunty TM; Linden J; Campochiaro PA
Curr Eye Res; 1991 Sep; 10(9):811-6. PubMed ID: 1665120
[TBL] [Abstract][Full Text] [Related]
28. Pressor-type vasopressin receptors in the adrenal cortex: properties of binding, effects on phosphoinositide metabolism and aldosterone secretion.
Balla T; Enyedi P; Spät A; Antoni FA
Endocrinology; 1985 Jul; 117(1):421-3. PubMed ID: 2988926
[TBL] [Abstract][Full Text] [Related]
29. Evidence that monensin inhibits vasopressin-stimulated water flow at an early step in the receptor-adenylate cyclase sequence.
Franki N; Mosenkis B; Hays RM
Biol Cell; 1989; 66(1-2):19-22. PubMed ID: 2478241
[TBL] [Abstract][Full Text] [Related]
30. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action and structural requirements of vasopressin analog inhibition of transepithelial water flux in toad urinary bladder.
Mann WA; Stassen F; Huffman W; Kinter LB
J Pharmacol Exp Ther; 1986 Aug; 238(2):401-6. PubMed ID: 3090234
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the effect of arginine-vasopressin on water and ion transport in the newt early distal tubule and frog urinary bladder by V1-antagonists.
Goncharevskaya OA; Shakhmatova EI; Natochin YV
Pflugers Arch; 1995 Oct; 430(6):1004-11. PubMed ID: 8594534
[TBL] [Abstract][Full Text] [Related]
33. Persistent stimulation of adenylate cyclase and urea transport by an AVP photolabel.
Eggena P; Ma CL; Fahrenholz F; Schwartz IL
Am J Physiol; 1985 Jul; 249(1 Pt 1):C84-8. PubMed ID: 3160246
[TBL] [Abstract][Full Text] [Related]
34. Internalization of fluorescent vasotocin-receptor agonist and antagonist in the toad bladder.
Eggena P; Lu M; Buku A
Am J Physiol; 1990 Sep; 259(3 Pt 1):C462-70. PubMed ID: 2119144
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
Ferris CF; Singer EA; Meenan DM; Albers HE
Eur J Pharmacol; 1988 Sep; 154(2):153-9. PubMed ID: 2976377
[TBL] [Abstract][Full Text] [Related]
36. Vasopressin stimulates inositol phospholipid metabolism in rat medulla oblongata in vivo.
Moratalla R; Vallejo M; Lightman SL
Brain Res; 1988 May; 450(1-2):398-402. PubMed ID: 2969763
[TBL] [Abstract][Full Text] [Related]
37. V1 vs. combined V1+V2 vasopressin blockade after hemorrhage in conscious dogs.
Liard JF
Am J Physiol; 1988 Dec; 255(6 Pt 2):H1325-9. PubMed ID: 2974249
[TBL] [Abstract][Full Text] [Related]
38. Central effects of vasopressin and 1-desamino-8-D-arginine vasopressin (DDAVP) on interleukin-1 fever in the rat.
Naylor AM; Gubitz GJ; Dinarello CA; Veale WL
Brain Res; 1987 Jan; 401(1):173-7. PubMed ID: 2949799
[TBL] [Abstract][Full Text] [Related]
39. Multiple signaling pathways of V1-vascular vasopressin receptors of A7r5 cells.
Thibonnier M; Bayer AL; Simonson MS; Kester M
Endocrinology; 1991 Dec; 129(6):2845-56. PubMed ID: 1659517
[TBL] [Abstract][Full Text] [Related]
40. Modulation of vasopressin action by reducing agents in Bufo marinus.
Butkus DE; Schwartz JH
Am J Physiol; 1982 Jul; 243(1):C52-61. PubMed ID: 6283908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
